BSECentuple Global Ltd· Pharmaceuticals & BiotechnologyHighNeutral
Announced Tue, 16 Sept, 2025 · 16:41 IST

Appointment of Mr. Shubham Chaudhary as CFO of the company w.e.f. September 17, 2025

Cfo ResignedKmp ResignedManagement Changes View source PDFExplain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+2.0%Reaction day
₹43.46
prior close
—
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+0.6%+1.3% vs market
Pharmaceuticals peers, median of 154sector+0.1%+1.9% vs sector

On the reaction day the stock moved 1.3 pts more than Nifty Microcap 250 and 1.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
—
10m
—
15m
—
30m
—
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+2.0+0.6+1.3+0.1+1.9
Next day
+4.0+0.4+3.6+0.2+3.8
2d
+1.9+0.8+1.2+0.2+1.8
3d
-0.1+0.0-0.1-0.7+0.6
4d
+1.9-0.3+2.2-1.0+2.9
5d
+3.9-0.6+4.6-1.1+5.0
1w
+8.1-3.8+11.8-4.0+12.1
15d
+26.5-2.9+29.4-3.5+30.0
1m
+42.4-2.9+45.3-4.1+46.5
2m
+91.2-1.5+92.7-5.1+96.3
3m
+141.9-8.1+149.9-8.3+150.2
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 154Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Checkpoint Trends Limited has informed the BSE that Ms. Abha Rajesh Kapoor (DIN: 02799429) resigned from her roles as Whole-Time Director and Chief Financial Officer effective September 16, 2025, citing personal reasons and pre-occupation. To fill the vacancy, the company has appointed Mr. Shubham Chaudhary (DIN: 09298013) as the new Chief Financial Officer effective September 17, 2025. Mr. Shubham Chaudhary was already serving as Whole-Time Director of the company since March 06, 2025, and will now hold both the WTD and CFO roles. The outgoing CFO confirmed there are no other material reasons behind her resignation.

Likely market impact

This is a smooth internal transition as the incoming CFO is already on the board as Whole-Time Director, minimizing any leadership gap. Shareholders should note that the company has combined the WTD and CFO roles into one person, which may warrant attention to governance balance but is common in small-cap companies.